TMEPAI (transmembrane prostate androgen-induced) is amplified at genomic, transcript and protein levels in triple-negative breast cancers and promotes TGF-β dependent growth, motility and invasion. This evidence concerns the gene TGFB1 and triple-negative breast carcinoma.